Argenx Receives FDA Approval for Vyvgart Label Expansion
Argenx announced the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The approved supplemental Biologics License Application expands Vyvgart's indication to include all serotypes of adult patients living with gMG - anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative.
